NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Sees Significant Decrease in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) was the recipient of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 1,200 shares, a decline of 69.2% from the November 30th total of 3,900 shares. Based on an average daily volume of 4,800 shares, the days-to-cover ratio is presently 0.3 days.

NRx Pharmaceuticals Trading Down 31.8 %

Shares of NRXPW traded down $0.03 on Friday, reaching $0.07. 3,174 shares of the company’s stock were exchanged, compared to its average volume of 15,166. NRx Pharmaceuticals has a 12 month low of $0.04 and a 12 month high of $0.39. The business has a 50 day moving average price of $0.06 and a two-hundred day moving average price of $0.07.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.